Glucagon-like peptide 1 (GLP-1): a promising approach and a novel treatment for patients with type 2 diabetes
FDA Adverse Event Reporting System (FAERS) data may include reports of musculoskeletal symptoms in patients using GLP-1 receptor agonists, though these reports do not establish causation and may reflect coincidental timing rather than a true drug effect
Response varies widely between individuals, partly due to differences in how patients metabolize bupropion and respond to dopaminergic stimulation
"Even in that population, retatrutide demonstrated nearly 21 percent average weight loss at the highest dose, which is remarkable." Retatrutide Also Delivered Significant Results for People With Severe Obesity and Heart Disease The other trial, TRIUMPH-3, included nearly 2,000 adults with severe obesity (defined as a BMI of 40 or higher) and cardiovascular disease
Accordant with the clamp data, Dpp4 hep/ mice had significantly reduced glucose excursion AUC after injection of pyruvate compared with littermate Dpp4 GFP controls (Figure 2A)